BioSpaceOriginal article
Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
Data ReadoutnegativeVyvgartNegative
AI Analysis
Summary
Argenx terminated its Sjogren's syndrome trial for Vyvgart due to a futility finding, representing a lost expansion opportunity for the blockbuster drug. The stock declined over 13% following the announcement, though the company achieved a mid-stage positive result in celiac disease from its $2.2 billion acquisition of Forte Biosciences.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Futility finding in Sjogren's syndrome study
Importance:7/10
Sentiment:
-0.80
trial terminationfutilitySjogren's syndromeVyvgartacquisitionForte Biosciencesceliac disease
Related Companies
Read the original article
Published by BioSpace on October 8, 2026 3:08 PM